Citadel Advisors’s Aptose Biosciences, Inc. APTO Stock Holding History

Citadel Advisors’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-24	Closed	-$15K	–	14593
2022 Q1	$15K	Sell	24 -137	-85%	-$75.8K	﹤0.01%	13319
2021 Q4	$98K	Sell	161 -124	-44%	-$117K	﹤0.01%	12746
2021 Q3	$279K	Buy	285 +93	+48%	+$116K	﹤0.01%	11212
2021 Q2	$288K	Buy	192 +62	+48%	+$135K	﹤0.01%	11374
2021 Q1	$348K	Sell	130 -23	-15%	-$45.6K	﹤0.01%	10499
2020 Q4	$302K	Buy	153 +104	+212%	+$244K	﹤0.01%	9068
2020 Q3	$133K	Buy	49 +27	+123%	+$67.3K	﹤0.01%	9090
2020 Q2	$64K	Buy	+22	New	+$71K	﹤0.01%	9202

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

CSC

Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return

Citadel Advisors's APTO Position: Q2 2025 in Review

Citadel Advisors sold out of Aptose Biosciences, Inc. (APTO) in Q2 2025, closing a stake of 12,007 shares — an estimated $38K sold.

Citadel Advisors first reported a position in APTO in Q3 2018 and held it in 20 quarters. The position peaked at $9.07M in Q3 2020. 4 funds tracked by Wall St. Rank hold APTO as of Q2 2025.

Citadel Advisors reported no remaining Aptose Biosciences, Inc. position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 12,007 Aptose Biosciences, Inc. shares in Q2 2025, an estimated $38K.
Citadel Advisors first reported a position in Aptose Biosciences, Inc. in Q3 2018 and held it in 20 quarters.
Citadel Advisors's Aptose Biosciences, Inc. position peaked at $9.07M in Q3 2020.
4 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.